Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.

Cybrexa Regains Rights to CBX-12 NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...

Cybrexa Therapeutics to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference NEW HAVEN, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...

Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021 NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...